<DOC>
	<DOCNO>NCT00704704</DOCNO>
	<brief_summary>Study Objectives The aim study evaluate safety efficacy combination 5-Aza-Cytidine + Thalidomide course hrMDS patient . Primary end point : • To evaluate overall response rate ( CR+PR ) combination 5-Aza-Cytidine + Thalidomide hrMDS patient ( INT-2 High risk define IPSS ) . Secondary end point : - To evaluate safety combination Thalidomide+5-Aza-Cytidine high risk MDS patient . - Hematological improvement rate . - Cytogenetic response . - Progression free survival ( PFS ) . - Quality life assessment ( FACT : MDS peripheral neuropathy QOL Questionnaires ) . Study design : This multicenter , phase II , single arm study design evaluate safety efficacy combination Thalidomide+5-Aza-Cytidine high risk MDS patient ( INT-2 High risk define IPSS ) old 18 year age . Potential study subject sign inform consent prior undergo study related procedure . Number patient enrol 50 . Treatment plan : 5-aza-cytidine ( 75 mg m2/d ) inject subcutaneously 5-day cycle every 28 day , total 12 cycle . Thalidomide give dose 50 mg/d , day 1 6 month together 5-aza-cytidine . Treatment period include 5-aza-cytidine ( 75 mg m2/d ) inject subcutaneously 5-day cycle every 28 day . Total number 12 cycle progression toxicity . Cycle delay maximum 2 week case hematological toxicity grade 3-4 investigator discretion . Duration follow period 6 month . Duration study The duration treatment period approximately 12 month . This time required complete treatment , determine safety profile response rate . The duration Follow period approximately half year . The occurrence PD determine duration progression-free survival patient .</brief_summary>
	<brief_title>Safety Efficacy Azacitidine , Thalidomide Higher Risk MDS ( Myelodysplastic Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Patient old 18 year time signing informed consent . Female patient either postmenopausal surgically sterilize willing use acceptable double method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Female childbearing potential must negative serum βhuman chorionic gonadotropin ( beta sub unitHCG ) pregnancy test 24 hour prior begin therapy 4 week interval woman regular menstrual cycle every 2 week woman irregular menstrual cycle study treatment subject childbearing potential . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) study drug therapy ( include dose interruption ) 4 week discontinuation thalidomide therapy . Patient diagnose myelodysplastic syndrome INT2 High risk accord IPSS score .Bone marrow aspiration examination include cytogenetics perform 12 month patient signing informed consent . Patient Performance Status 02 ( WHO ) . Patient lifeexpectancy &gt; 6 month Patient know active infectious hepatitis type B C , HIV infection . Patient epopoietin resistant . Erythropoietin discontinue 28 day start treatment period . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 ) : Platelet count ≥ 25 x 109/L without transfusion support within 7 day test . Absolute neutrophil count ( ANC ) ≥ 0.5 x 109/L without use growth factor . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal ( ULN ) . Alanine transaminase ( ALT ) : ≤ 2.5 x ULN . Total bilirubin : ≤ 1.5 x ULN . Serum creatinine &lt; 2 X ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>high risk MDS</keyword>
	<keyword>IPSS</keyword>
	<keyword>5-AZA-Cytidine</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>response rate</keyword>
	<keyword>cytogenetic response</keyword>
	<keyword>QOL questionaries</keyword>
	<keyword>INT-2 High risk MDS</keyword>
</DOC>